Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes
Genprex, Inc. (GNPX)
Last genprex, inc. earnings: 11/14 12:08 pm
Check Earnings Report
Company Research
Source: Business Wire
Company licenses patented diabetes gene therapy technology designed by researchers at the University of PittsburghResults from in vivo animal studies indicate that normal glucose levels in the blood may be restored for an extended period of timeCompany plans to partner for the clinical development and commercialization of this therapy in the U.S. and internationally AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced that it signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.This press release features multimedia. View the full release here: https:
Show less
Read more
Impact Snapshot
Event Time:
GNPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNPX alerts
High impacting Genprex, Inc. news events
Weekly update
A roundup of the hottest topics
GNPX
News
- Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung CancerPR Newswire
- Genprex doses first subject in expansion part of lung cancer gene therapy trial [Yahoo! Finance]Yahoo! Finance
- Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerPR Newswire
- Genprex Advances Cancer Trials and Diabetes Therapy [Yahoo! Finance]Yahoo! Finance
GNPX
Sec Filings
- 2/12/25 - Form 8-K
- 1/24/25 - Form S-8
- 1/23/25 - Form 8-K
- GNPX's page on the SEC website